Hopes dashed for peanut allergy drug Xolair
Key points
- Hopes have been dashed for a potential treatment for peanut allergies following the severe reactions suffered by two children during a clinical trial.
- Genentech is one of the largest biotech companies in the world, and was conducting clinical trials of their drug Xolair in order to test whether the drug could prevent reactions to peanut allergies.
- Of the 150 children in the trial, two apparently experienced "severe hypersensitivity reactions" to a trace amount of peanut protein.
- It seems the children had not been given Xolair, but were given the protein to test their reactions.
Hopes have been dashed for a potential treatment for peanut allergies following the severe reactions suffered by two children during a clinical trial.
Biotech company Genentech, Inc. has now stopped the trials.
Genentech is one of the largest biotech companies in the world, and was conducting clinical trials of their drug Xolair in order to test whether the drug could prevent reactions to peanut allergies.
Of the 150 children in the trial, two apparently experienced "severe hypersensitivity reactions" to a trace amount of peanut protein.
It seems the children had not been given Xolair, but were given the protein to test their reactions.
According to a Genentech spokeswoman they will not carry out that procedure again.
Xolair is already available on the market as a treatment for allergic asthma and it is not uncommon for drug manufacturers to test products for additional uses after they've already been approved.
Genentech's top-selling products are Rituxan, a treatment for non-Hodgkin's lymphoma and Avastin, a treatment for colorectal cancer.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Lungs, Asthma & Allergies →NewsBlood test predicts severity of peanut and seafood allergies
A new blood test promises to predict which people will have severe allergic reactions to foods according to a new study led by Mount Sinai researchers and published online today in the The Annals of Allergy, Asthma &…
2 April 2015
NewsDo genes play a role in peanut allergies? New study suggests - YES
Researchers have pinpointed a region in the human genome associated with peanut allergy in U.S. children, offering strong evidence that genes can play a role in the development of food allergies. But in an additional…
25 February 2015
NewsResistance to anti-viral drug may be more likely in cystic fibrosis patients
A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation. Ganciclovir reduces mortality due to the virus from 34 percent to between…